To the top

Page Manager: Webmaster
Last update: 9/11/2012 3:13 PM

Tell a friend about this page
Print version

A Genome-wide Study of Co… - University of Gothenburg, Sweden Till startsida
Sitemap
To content Read more about how we use cookies on gu.se

A Genome-wide Study of Common and Rare Genetic Variants Associated with Circulating Thrombin Activatable Fibrinolysis Inhibitor

Journal article
Authors Tara M Stanne
Maja Olsson
Erik Lorentzen
Annie Pedersen
Anders Gummesson
A. Gils
Katarina Jood
G. Engstrom
O. Melander
P. J. Declerck
Christina Jern
Published in Thrombosis and Haemostasis
Volume 118
Issue 2
Pages 298-308
ISSN 0340-6245
Publication year 2018
Published at Institute of Biomedicine, Department of Pathology
Core Facilities, Bioinformatics
Institute of Neuroscience and Physiology, Department of Clinical Neuroscience
Pages 298-308
Language en
Links doi.org/10.1160/TH17-04-0249
Keywords thrombin-activatable fibrinolysis inhibitor, fibrinolysis inhibitors, plasma levels, genome-wide, plasma procarboxypeptidase b, coronary-artery-disease, tafi antigen, levels, ischemic-stroke, mediated activation, risk, identification, polymorphisms, genotype, expression, Hematology, Cardiovascular System & Cardiology
Subject categories Cardiac and Cardiovascular Systems, Cardiovascular medicine, Hematology

Abstract

Thrombin-activatable fibrinolysis inhibitor (TAFI) plays a central role in haemostasis, and plasma TAFI concentrations are heritable. Candidate gene studies have identified several variants within the gene encoding TAFI, CPB2, that explain part of the estimated heritability. Here, we describe an exploratory genome-wide association study to identify novel variants within and outside of the CPB2 locus that influence plasma concentrations of intact TAFI and/or the extent of TAFI activation (measured by released TAFI activation peptide, TAFI-AP) amongst 3,260 subjects from Southern Sweden. We also explored the role of rare variants on the HumanExome BeadChip. We confirmed the association with previously reported common variants in CPB2 for both intact TAFI and TAFI-AP, and discovered novel associations with variants in putative CPB2 enhancers. We identified a gene-based association with intact TAFI at CPB2 (PSKAT-O = 2.8 x 10(-8)), driven by two novel rare nonsynonymous single nucleotide polymorphisms (SNPs; I420N and D177G). Carriers of the rare variant of D177G (rs140446990; MAF 0.2%) had lower intact TAFI and TAFI-AP concentrations compared with non-carriers (intact TAFI, geometricmean 53 vs. 78%, PT-test < 5 x 10(-7); TAFI-AP 63 vs. 99%, P(T-tes)t = 7.2 x 10(-4)). For TAFI-AP, we identified a genome-wide significant association at an intergenic region of chromosome 3p14.1 and five gene-based associations (all PSKAT-O = 5 x 10(-6)). Using well-characterized assays together with a genome-wide association study and a rare-variant approach, we verified CPB2 to be the primary determinant of TAFI concentrations and identified putative secondary loci (candidate variants and genes) associated with intact TAFI and TAFI-AP that require independent validation.

Page Manager: Webmaster|Last update: 9/11/2012
Share:

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?

Denna text är utskriven från följande webbsida:
http://www.gu.se/english/research/publication/?publicationId=264563
Utskriftsdatum: 2019-12-11